title: Cancer genomics identifies disrupted epigenetic genes.
abstract: Latest advances in genome technologies have greatly advanced the discovery of epigenetic genes altered in cancer. The initial single candidate gene approaches have been coupled with newly developed epigenomic platforms to hasten the convergence of scientific discoveries and translational applications. Here, we present an overview of the evolution of cancer epigenomics and an updated catalog of disruptions in epigenetic pathways, whose misregulation can culminate in cancer. The creation of these basic mutational catalogs in cell lines and primary tumors will provide us with enough knowledge to move diagnostics and therapy from the laboratory bench to the bedside.
authors.affiliation: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 3rd Floor, Hospital Duran i Reynals, Av. Gran Vía 199-203, L'Hospitalet, 08907, Barcelona, Catalonia, Spain.
authors.forename: Laia
authors.initials: L
authors.lastname: Simó-Riudalbas
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
mesh_terms: D045744:Cell Line, Tumor; D002843:Chromatin / Q000737:chemistry; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D015894:Genome, Human; D023281:Genomics / Q000379:methods* / Q000639:trends; D006657:Histones / Q000235:genetics / Q000378:metabolism; D006801:Humans; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D022661:RNA, Untranslated / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D057170:Translational Research, Biomedical
chemical_list: D002843:Chromatin; D006657:Histones; D009363:Neoplasm Proteins; D022661:RNA, Untranslated